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After publication of our recent article [1], we noticed an error
in Table 6 ‘Relative risk for developing rheumatoid arthritis in
patients, stratified for anti-cyclic citrullinated peptide (anti-
CCP) antibodies’.
Under the heading of ‘Anti-CCP antibody-positive’, the first
line should read ‘HLA-shared epitope-negative’, and the
second line should read ‘HLA-shared epitope-positive’.
Similarly, under the heading ‘Anti-CCP antibody-negative’, the
first line should read ‘HLA-shared epitope-negative’ and the
second line should read ‘HLA-shared epitope-positive’.
The correct table is given here as Table 1 (a corrected
version of Table 6 [1]).
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Table 1
Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies
Nonsmoking Smoking
Relative risk  Relative risk 
Cases/controls (95% confidence interval) Cases/controls confidence interval)
Anti-CCP antibody-positive
HLA-shared epitope-negative 33/41 1.00 71/49 1.67 (0.95-2.94)
HLA-shared epitope-positive 62/33 2.05 (1.12-3.75) 143/21 7.61 (4.05-14.30)
Anti-CCP antibody-negative
HLA-shared epitope-negative 40/41 1.00 52/49 1.11 (0.63-1.95)
HLA-shared epitope-positive 23/33 0.71 (0.37-1.38) 31/21 1.92 (0.98-3.77)
The combination of carriage of HLA-shared epitope alleles or not, and ever or never smoking were compared for groups stratified for anti-CCP
antibodies.